Source: Healio News
Long-term results from the KarMMa trial continued to yield frequent deep and durable responses with idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in heavily pretreated patients with relapsed or refractory multiple myeloma.
Based on early results from KarMMa, idecabtagene vicleucel (ide-cel; Abecma; Bristol Myers Squibb, bluebird bio) the FDA granted approval for use in patients with relapsed/refractory multiple myeloma after at least four prior lines of therapy.
“The objective of this analysis was to present longer term efficacy and safety results in patients treated with